Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.

Jin Ng Ling Cai Luc Girard Owen William John Prall Neeha Rajan Christine Khoo Ahida Batrouney David J Byrne Danielle K Boyd Ariena J Kersbergen Michael Christie John D Minna Marian L Burr Kate D Sutherland

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

SMARCA4-mutant SCLC-Y cell lines exhibit characteristics consistent with SMARCA4-deficient malignancies rather than SCLC. Our findings suggest that, unlike ASCL1, NEUROD1, and POU2F3, YAP1 is not a subtype defining transcription factor in SCLC. See related commentary by Rekhtman, p. 1708.

Keyphrases

small cell lung cancer
wild type
transcription factor
neoadjuvant chemotherapy
brain metastases
dna binding
radiation therapy